152 related articles for article (PubMed ID: 33823082)
1. Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers.
Bernicker EH; Xiao Y; Abraham A; Yang B; Croix DA; Redpath S; Engstrom-Melnyk J; Shah R; Madala J; Allen TC
Oncologist; 2021 Jun; 26(6):e1050-e1057. PubMed ID: 33823082
[TBL] [Abstract][Full Text] [Related]
2. Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.
Lin HM; Wu Y; Yin Y; Niu H; Curran EA; Lovly CM; Humphries MJ
Clin Lung Cancer; 2023 Jan; 24(1):e39-e49. PubMed ID: 36376172
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
John A; Yang B; Shah R
Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
[TBL] [Abstract][Full Text] [Related]
4. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
Davies J; Martinec M; Coudert M; Delmar P; Crane G
Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
6. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
7. Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand.
McKeage MJ; Tin Tin S; Khwaounjoo P; Sheath K; Dixon-McIver A; Ng D; Sullivan R; Cameron L; Shepherd P; Laking GR; Kingston N; Strauss M; Lewis C; Elwood M; Love DR
Intern Med J; 2020 Jun; 50(6):716-725. PubMed ID: 31318119
[TBL] [Abstract][Full Text] [Related]
8. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
9. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
[No Abstract] [Full Text] [Related]
10. Understanding Factors Associated With Anaplastic Lymphoma Kinase Testing Delays in Patients With Non-Small Cell Lung Cancer in a Large Real-World Oncology Database.
Bernicker EH; Xiao Y; Croix DA; Yang B; Abraham A; Redpath S; Engstrom-Melnyk J; Shah R; Allen TC
Arch Pathol Lab Med; 2022 Aug; 146(8):975-983. PubMed ID: 34752598
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa.
Jazieh AR; Gaafar R; Errihani H; Jaafar H; Al Dayel F; Bahnassy AA; El Kadi H; Abdallah MM; Zaatari G
JCO Glob Oncol; 2021 Sep; 7():1556-1563. PubMed ID: 34788123
[TBL] [Abstract][Full Text] [Related]
13. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
14. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
Sheinson D; Wong WB; Wu N; Mansfield AS
Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
[TBL] [Abstract][Full Text] [Related]
15. Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis.
Itchins M; Hayes SA; Gill AJ; Cooper W; O'Connell R; Howell VM; Clarke SJ; Pavlakis N
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e275-e282. PubMed ID: 29675948
[TBL] [Abstract][Full Text] [Related]
16. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
Mendoza DP; Stowell J; Muzikansky A; Shepard JO; Shaw AT; Digumarthy SR
Clin Lung Cancer; 2019 Sep; 20(5):339-349. PubMed ID: 31164317
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F
BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data.
Allen TC; Xiao Y; Yang B; Croix D; Abraham A; Redpath S; Engstrom-Melynk J; Shah R; Madala J; Bernicker EH
Oncotarget; 2021 Nov; 12(23):2308-2315. PubMed ID: 34786182
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
